Table 1.
Clinical parameters of EAE after i.v. tolerance and administration of exogenous IL-17.
| Mice | Incidence (%)a | Mean day of disease onset (± SEM) b | Mean maximum score (± SEM) | Mean cumulative score (± SEM) c | Area under curve (± SEM) |
|---|---|---|---|---|---|
| EAE + PBS (n = 10) | 100 | 12.3 ± 0.2 | 3.3 ± 0.2 | 20.4 ± 1.1 | 18.9 ± 1.1 |
| EAE + IL-17 (n = 10) | 100 | 12.0 ± 0.4 | 3.6 ± 0.1 | 22.9 ± 0.9 * | 21.6 ± 0.9 * |
| EAE + MOG i.v. (n = 10) | 50 | 16.8 ± 1.1 | 0.4 ± 0.1 | 2.4 ± 0.9 | 2.2 ± 0.8 |
| EAE +MOG i.v. + IL-17 (n = 10) | 90 | 15.1 ± 0.9 | 1.2 ± 0.2 # | 5.2 ± 1.0 # | 4.7 ± 1.0 # |
EAE and i.v. tolerance induction and IL-17 administration was described in Fig. 2 and in Materials and Methods section.
a
Disease incidence is defined as the percentage of mice that displayed any clinical signs of disease.
b
Mean day of disease onset is defined as the first day of 2 consecutive days with a clinical score of 0.5 or more.
c
Mean cumulative score is defined as the mean of the sum of daily clinical scorers observed between days 12 and 20.
* refers to comparison between EAE + PBS and EAE + IL-17; # refers to comparison between EAE + MOG i.v. and EAE + MOG i.v. + IL-17. * and #, p<0.05.